Non-Invasive Prediction of Mutation in Patients with Glioma WHO II/III/IV Based on F-18-FET PET-Guided In Vivo H-Magnetic Resonance Spectroscopy and Machine Learning.

( mutation is an important prognostic factor and a potential therapeutic target in glioma. Immunohistological and molecular diagnosis of mutation status is invasive. To avoid tumor biopsy, dedicated spectroscopic techniques have been proposed to detect D-2-hydroxyglutarate (2-HG), the main metabolite of , directly in vivo.